Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (151-160 of 201) with videos related to

Pageof 21
Sort By:
Scientific Reports|June 15, 2019
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
Neurology|August 17, 2016
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosisShivani Ahlawat, Laura M Fayad, Muhammad Shayan Khan, et al.
Neurology|July 7, 2021
Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical TrialsRaquel D Thalheimer, Vanessa L Merker, K Ina Ly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Science Advances|May 1, 2024
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1Kavita Y Sarin, Mark Bradshaw, Chris O'Mara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Nature Protocols|January 9, 2019
A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannomaJie Chen, Lukas D Landegger, Yao Sun, et al.
Neuro-Oncology|August 8, 2014
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningiomaThomas J Kaley, Patrick Wen, David Schiff, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma ModelSimeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2018
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma modelsYingchao Zhao, Pinan Liu, Na Zhang, et al.
Pageof 21

Showing results (151-160 of 201) with videos related to

Sort By:
Pageof 21
Scientific Reports|June 15, 2019
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
Neurology|August 17, 2016
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosisShivani Ahlawat, Laura M Fayad, Muhammad Shayan Khan, et al.
Neurology|July 7, 2021
Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical TrialsRaquel D Thalheimer, Vanessa L Merker, K Ina Ly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Science Advances|May 1, 2024
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1Kavita Y Sarin, Mark Bradshaw, Chris O'Mara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Nature Protocols|January 9, 2019
A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannomaJie Chen, Lukas D Landegger, Yao Sun, et al.
Neuro-Oncology|August 8, 2014
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningiomaThomas J Kaley, Patrick Wen, David Schiff, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma ModelSimeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2018
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma modelsYingchao Zhao, Pinan Liu, Na Zhang, et al.
Pageof 21